Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.
Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.